Untested combination Performance and Recovery
CJC-1295 + GHRP-2 blend
Also called CJC/GHRP-2
A research blend pairing a GHRH analogue with a ghrelin-receptor secretagogue. The pathway rationale is real, but the blend itself has not been tested in people.
Overview
What it is
CJC-1295 (a GHRH analogue) plus GHRP-2 (pralmorelin). See each ingredient's entry.
How it works
GHRH and ghrelin-receptor pathways can boost growth hormone release together in human research, though the studied compounds and routes differ from this blend.
What the research shows
CJC-1295 with DAC raised growth hormone and IGF-1 for days in healthy adults. GHRP-2 raises growth hormone and appetite acutely. No trial of the blend was identified.
Studied for
- Growth hormone releaseingredients separately
Safety and regulatory status
Safety and side effects
GHRP-2 can increase appetite and briefly raise ACTH, cortisol and prolactin; CJC-1295 can cause flushing and lightheadedness. FDA lists both on its compounding safety-risk list.
Regulatory status
Not FDA approved. Both ingredients are prohibited in sport.
Mixing and dosing reference
Reference information only. Read before using this section.
Reference information only. Not instructions. These mixing and dosing figures summarize published studies and third-party protocols so you can understand the research. They are not medical advice, not a recommendation that anyone use any substance, and not a treatment plan. They do not apply to Research Products, which are for laboratory research only and must never be used in humans or animals. Never self-administer any compound. Only a licensed healthcare professional who has evaluated you can decide whether a medication is appropriate and how it should be used.
CJC-1295 + GHRP-2 (10 mg Blend) Dosage Protocol
- Vial
- 10 mg total blend
- Add diluent
- 3 mL
- Concentration
- 3.33 mg/mL
- 1 unit (U-100)
- 33.33 mcg total in 0.01 mL
- Route
- Subcutaneous
- How often
- Once per day (subcutaneous), preferably evening/bedtime.
- Typical range
- 100–300 mcg once daily (gradual titration).
- Cycle length
- 8–12 weeks; optional extension to 16 weeks.
Standard / Gradual Approach
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 150 mcg (0.15 mg) | 4.5 units (0.045 mL) |
| Weeks 3–12 | 300 mcg (0.30 mg) | 9 units (0.09 mL) |
Advanced / Twice-Daily Approach
| Week | Dose per Injection (mcg) | Units (per injection) (mL) | Total Daily (mcg) |
|---|---|---|---|
| Weeks 1–2 | 100 mcg (0.10 mg) | 3 units (0.03 mL) | 200 mcg |
| Weeks 3–12 | 150 mcg (0.15 mg) | 4.5 units (0.045 mL) | 300 mcg |
How to mix
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Dosing details
- Start: 100–150 mcg daily for Weeks 1–2 to allow acclimatization.
- Target: 250–300 mcg daily by Weeks 3–12.
- Frequency: Once per day (subcutaneous), preferably evening/bedtime.
- Cycle Length: 8–12 weeks; optional extension to 16 weeks.
- Timing: Inject on an empty stomach; rotate injection sites.
Storage
- Lyophilized: Follow each component vial’s labeled storage temperature and expiration instructions.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); follow formulation-specific use-by and sterile-handling instructions.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
- Do not assume aliquoting or freezing a reconstituted blend extends stability or sterility; avoid repeated freeze–thaw.
Administration technique
- Clean the vial stopper and skin with alcohol; allow to dry.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
- Do not aspirate for subcutaneous injections; inject slowly and steadily.
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid local tissue changes.
- Withdraw the needle at the same angle; dispose immediately in a sharps container.
Important notes
- Use new sterile insulin syringes for each injection; dispose in a sharps container.
- Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
- Inject slowly on an empty stomach; GHRP-2’s GH response may be blunted by elevated blood glucose.
- Document daily dose and site rotation to maintain consistency.
- No post-cycle therapy is required; GH and IGF-1 levels return to baseline after cessation.
Protocol source: PeptideDosages.com
Common questions
Does combining them work better?
Pathway research suggests a larger GH response, but no trial shows better health outcomes.
Related in Performance and Recovery
Sources and further reading (3)
- Teichman SL, et al. CJC-1295 in healthy adults. JCEM, 2006.
- Laferrère B, et al. GHRP-2 increases food intake, 2005.
- Source summary: PeptideDosages.com research overview (rewritten for NVO).
Educational information only. This content summarizes published research for general education. It is not medical advice, not a recommendation to use any substance, and not an instruction for human or animal use. It does not describe any Research Product sold on this site.